A new era of medical therapy for peripheral artery disease

Casella, Ivan Benaduce; Presti, Calógero

doi:10.1590/1677-5449.190056

Cited by 1 publication

(1 citation statement)

References 20 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 373 Though the basic principle indicates that P-selectin antagonist inclacumab is able to improve the development of peripheral artery disease, evidence from clinical studies is lacking. 374 …”

Section: Atherosclerosis Therapiesmentioning

confidence: 99%

Inflammation and atherosclerosis: signaling pathways and therapeutic intervention

Kong

Cui

Huang

et al. 2022

Sig Transduct Target Ther

218

View full text Add to dashboard Cite

Atherosclerosis is a chronic inflammatory vascular disease driven by traditional and nontraditional risk factors. Genome-wide association combined with clonal lineage tracing and clinical trials have demonstrated that innate and adaptive immune responses can promote or quell atherosclerosis. Several signaling pathways, that are associated with the inflammatory response, have been implicated within atherosclerosis such as NLRP3 inflammasome, toll-like receptors, proprotein convertase subtilisin/kexin type 9, Notch and Wnt signaling pathways, which are of importance for atherosclerosis development and regression. Targeting inflammatory pathways, especially the NLRP3 inflammasome pathway and its regulated inflammatory cytokine interleukin-1β, could represent an attractive new route for the treatment of atherosclerotic diseases. Herein, we summarize the knowledge on cellular participants and key inflammatory signaling pathways in atherosclerosis, and discuss the preclinical studies targeting these key pathways for atherosclerosis, the clinical trials that are going to target some of these processes, and the effects of quelling inflammation and atherosclerosis in the clinic.

show abstract

Section: Atherosclerosis Therapiesmentioning

confidence: 99%